All sponsors

Replimune, Inc.

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS6
PHASE 3 / 2-32
RECRUITING3
READOUTS ≤12 MONTHS0
READOUT SLIPPED >6 MO80%

Delay Index: of 5 active trials registered more than a year ago, 4 have moved their primary completion (readout) date by more than 6 months since first registration (median +20.9 months). See all sponsors →

Open Replimune, Inc. on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
CERPASS
NCT04050436
P2Active, not recruitingCutaneous Squamous Cell Carcinoma; Advanced Cutaneous Squamous Cell Carcinoma2312025-09
RP2
NCT05733598
P2RecruitingHepatocellular Carcinoma; Biliary Tract Cancer602027-12-01 (+11 mo)
IGNYTE
NCT03767348
P2Active, not recruitingNon-Small Cell Lung Cancer (NSCLC); Microsatellite Instability-High (MSI-H)3402028-06 (+79 mo)
ARTACUS
NCT04349436
P1/2Active, not recruitingMerkel Cell Carcinoma; Basal Cell Carcinoma692029-07 (+65 mo)
RP2
NCT06581406
P2/3RecruitingMetastatic Uveal Melanoma2802030-01
Vusolimogene Oderparepvec
NCT06264180
P3RecruitingAdvanced Melanoma4002030-09-30 (+21 mo)